IvelinRadkov/iStock via Getty Images
Avidity Biosciences (NASDAQ:RNA) has announced new data from its clinical trials evaluating the experimental treatment del-zota for Duchenne muscular dystrophy.
After one year of continuous treatment, participants showed not only a halt in disease progression, but also measurable improvements compared to their
American schools are at a crossroads. Artificial intelligence companies say their technology will completely reshape the workforce, and no one...
In March’s salary, employees earning more than NIS 16,150 per month, will receive several hundred more shekels net pay,...
The global stock market landscape has become increasingly complex, shaped by macroeconomic uncertainty, geopolitical risks, and shifting liquidity conditions. Yet,...
U.S. service member who has been missing since Iran shot down a fighter jet has been rescued, according to two...
If the U.S.-Israel war on Iran continues into the summer, then airlines will start running out of jet fuel and...
Phillippe Laffont has built a reputation as one of the world's best tech investors. His hedge fund, Coatue Management, is...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
